| 4883- | LT, | CHr, | BRU, | VitC, | An update of Nrf2 activators and inhibitors in cancer prevention/promotion |
| - | Review, | Var, | NA |
| 4687- | LT, | QC, | Dietary Flavonoids Luteolin and Quercetin Suppressed Cancer Stem Cell Properties and Metastatic Potential of Isolated Prostate Cancer Cells |
| - | in-vitro, | Pca, | DU145 |
| 2587- | LT, | Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs |
| - | in-vitro, | Lung, | A549 |
| 2588- | LT, | Chemo, | Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway |
| - | in-vitro, | CRC, | HCT116 |
| 2589- | LT, | Chemo, | Luteolin Inhibits Breast Cancer Stemness and Enhances Chemosensitivity through the Nrf2-Mediated Pathway |
| - | in-vitro, | BC, | MDA-MB-231 |
| 2925- | LT, | Luteolin Induces Carcinoma Cell Apoptosis through Binding Hsp90 to Suppress Constitutive Activation of STAT3 |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Nor, | HEK293 | - | in-vitro, | BC, | MCF7 |
| 2930- | LT, | Luteolin confers renoprotection against ischemia–reperfusion injury via involving Nrf2 pathway and regulating miR320 |
| - | in-vitro, | Nor, | NA |
| 2929- | LT, | Loss of BRCA1 in the cells of origin of ovarian cancer induces glycolysis: A window of opportunity for ovarian cancer chemoprevention |
| - | in-vitro, | Ovarian, | NA |
| 2928- | LT, | Luteolin-mediated increase in miR-26a inhibits prostate cancer cell growth and induces cell cycle arrest targeting EZH2 |
| 2927- | LT, | Luteolin Causes 5′CpG Demethylation of the Promoters of TSGs and Modulates the Aberrant Histone Modifications, Restoring the Expression of TSGs in Human Cancer Cells |
| - | in-vitro, | Cerv, | HeLa |
| 2926- | LT, | Luteolin ameliorates rat myocardial ischemia-reperfusion injury through peroxiredoxin II activation: LUT's cardioprotection through PRX II |
| - | in-vitro, | Nor, | H9c2 |
| 2924- | LT, | Luteolin selectively kills STAT3 highly activated gastric cancer cells through enhancing the binding of STAT3 to SHP-1 |
| - | in-vitro, | GC, | NA | - | in-vivo, | NA, | NA |
| 2923- | LT, | Luteolin induces apoptosis through endoplasmic reticulum stress and mitochondrial dysfunction in Neuro-2a mouse neuroblastoma cells |
| - | in-vitro, | NA, | NA |
| 2921- | LT, | Luteolin as a potential hepatoprotective drug: Molecular mechanisms and treatment strategies |
| - | Review, | Nor, | NA |
| 2906- | LT, | Luteolin, a flavonoid with potentials for cancer prevention and therapy |
| - | Review, | Var, | NA |
| 2907- | LT, | Protective effect of luteolin against oxidative stress‑mediated cell injury via enhancing antioxidant systems |
| - | in-vitro, | Nor, | NA |
| 2908- | LT, | Luteolin attenuates neutrophilic oxidative stress and inflammatory arthritis by inhibiting Raf1 activity |
| - | in-vitro, | Arthritis, | NA |
| 2909- | LT, | Revisiting luteolin: An updated review on its anticancer potential |
| - | Review, | Var, | NA |
| 2910- | LT, | FA, | Folic acid-modified ROS-responsive nanoparticles encapsulating luteolin for targeted breast cancer treatment |
| - | in-vitro, | BC, | 4T1 | - | in-vivo, | NA, | NA |
| 2911- | LT, | Luteolin targets MKK4 to attenuate particulate matter-induced MMP-1 and inflammation in human keratinocytes |
| - | in-vitro, | Nor, | HaCaT |
| 2912- | LT, | Luteolin: a flavonoid with a multifaceted anticancer potential |
| - | Review, | Var, | NA |
| 2913- | LT, | Luteolin induces apoptosis by impairing mitochondrial function and targeting the intrinsic apoptosis pathway in gastric cancer cells |
| - | in-vitro, | GC, | HGC27 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | GC, | MKN45 |
| 2905- | LT, | Luteolin blocks the ROS/PI3K/AKT pathway to inhibit mesothelial-mesenchymal transition and reduce abdominal adhesions |
| - | in-vivo, | NA, | HMrSV5 |
| 2904- | LT, | Luteolin from Purple Perilla mitigates ROS insult particularly in primary neurons |
| - | in-vitro, | Park, | SK-N-SH | - | in-vitro, | AD, | NA |
| 2914- | LT, | Therapeutic Potential of Luteolin on Cancer |
| - | Review, | Var, | NA |
| 2915- | LT, | Luteolin promotes apoptotic cell death via upregulation of Nrf2 expression by DNA demethylase and the interaction of Nrf2 with p53 in human colon cancer cells |
| - | in-vitro, | Colon, | HT29 | - | in-vitro, | CRC, | SNU-407 | - | in-vitro, | Nor, | FHC |
| 2903- | LT, | Luteolin induces apoptosis by ROS/ER stress and mitochondrial dysfunction in gliomablastoma |
| - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | U87MG | - | in-vivo, | NA, | NA |
| 2922- | LT, | Combination of transcriptomic and proteomic approaches helps unravel the mechanisms of luteolin in inducing liver cancer cell death via targeting AKT1 and SRC |
| - | in-vitro, | Liver, | HUH7 |
| 2920- | LT, | Formulation, characterization, in vitro and in vivo evaluations of self-nanoemulsifying drug delivery system of luteolin |
| - | in-vitro, | Nor, | NA | - | in-vivo, | Nor, | NA |
| 2919- | LT, | Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence |
| - | Review, | Var, | NA |
| 2918- | LT, | Luteolin inhibits melanoma growth in vitro and in vivo via regulating ECM and oncogenic pathways but not ROS |
| - | in-vitro, | Melanoma, | A375 | - | in-vivo, | Melanoma, | NA | - | in-vitro, | Melanoma, | SK-MEL-28 |
| 2917- | LT, | Rad, | Luteolin acts as a radiosensitizer in non‑small cell lung cancer cells by enhancing apoptotic cell death through activation of a p38/ROS/caspase cascade |
| - | in-vitro, | Lung, | NA |
| 2916- | LT, | Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 2346- | LT, | Luteolin suppressed PKM2 and promoted autophagy for inducing the apoptosis of hepatocellular carcinoma cells |
| - | in-vitro, | HCC, | HepG2 |
| 2595- | LT, | Regulation of Nrf2/ARE Pathway by Dietary Flavonoids: A Friend or Foe for Cancer Management? |
| - | Review, | Var, | NA |
| 1317- | LT, | Luteolin Suppresses Teratoma Cell Growth and Induces Cell Apoptosis via Inhibiting Bcl-2 |
| - | vitro+vivo, | Ovarian, | PA1 |
| 1200- | LT, | Inhibition of Fatty Acid Synthase by Luteolin Post-Transcriptionally Downregulates c-Met Expression Independent of Proteosomal/Lysosomal Degradation |
| - | in-vitro, | Pca, | DU145 |
| 1275- | LT, | Mechanism of luteolin induces ferroptosis in nasopharyngeal carcinoma cells |
| - | in-vitro, | Laryn, | NA |
| 1171- | LT, | The inhibition of β-catenin activity by luteolin isolated from Paulownia flowers leads to growth arrest and apoptosis in cholangiocarcinoma |
| - | in-vitro, | CCA, | NA |
| - | in-vitro, | Nor, | MCF10 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | PC, | Bxpc-3 |
| 8342- | Lut, | Cisplatin, | Lutein Influences Cisplatin Sensitivity Through Differential Regulation of DNA Damage Response Genes in Breast Cancer Cells |
| - | in-vitro, | Nor, | HUVECs | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF7 |
| 8343- | Lut, | Association of Lutein with Cancer: A Systematic Review of the Lutein Effects on Cellular Processes Involved in Cancer Progression |
| - | Review, | Var, | NA |
| 8344- | Lut, | NrF2/ARE and NF-κB pathway regulation may be the mechanism for lutein inhibition of human breast cancer cell |
| - | in-vitro, | BC, | NA |
| 8345- | Lut, | Lutein inhibits breast cancer cell growth by suppressing antioxidant and cell survival signals and induces apoptosis |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 |
| 8346- | Lut, | Lutein inhibits tumor progression through the ATR/Chk1/p53 signaling pathway in non-small cell lung cancer |
| - | vitro+vivo, | NSCLC, | A549 |
| 8348- | Lut, | Lutein inhibits proliferation, invasion and migration of hypoxic breast cancer cells via downregulation of HES1 |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA‑MB‑157 |
| 8347- | Lut, | Carotenoid Lutein Selectively Inhibits Breast Cancer Cell Growth and Potentiates the Effect of Chemotherapeutic Agents through ROS-Mediated Mechanisms |
| - | in-vitro, | BC, | NA |
| 8357- | Lut, | Comparison of lutein bioavailability from vegetables and supplement |
| - | Study, | Nor, | NA |
| 8349- | Lut, | Lutein Inhibits Cell Growth and Activates Apoptosis via the PI3K/AKT/mTOR Signaling Pathway in A549 Human Non-Small-Cell Lung Cancer Cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | HCC827 | - | in-vitro, | Nor, | BEAS-2B |
| - | in-vitro, | Nor, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid